Patient Possibilities footer references

September 12, 2012

References 1. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. [published errata appears in J Clin Oncol. 2011;29(16):2293] J Clin Oncol. 2010;28(30):4594-4600. 3. Data on File, 1137103. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 4. Data on File, 1196503. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 5. Data on File, 1390903. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 6. Data on File, 1373902. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

References 1. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg
with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
[published errata appears in J Clin Oncol. 2011;29(16):2293] J Clin Oncol. 2010;28(30):4594-4600. 3. Data on File, 1137103. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 4. Data on File, 1196503. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 5. Data on File, 1390903. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 6. Data on File, 1373902. AstraZeneca Pharmaceuticals LP, Wilmington, DE.